A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Phase 1/2
180
about 3.4 years
18+
3 sites in CO, FL, NY
About this study
Researchers are testing a treatment called STP938 in adults with relapsed or refractory B-cell and T-cell lymphomas. The trial will first determine the best dose of STP938 to use, then expand it to include more patients who are receiving this treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take STP938
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Objective Response Rate (ORR) (Phase 2 / Dose Expansion), Safety and Tolerability (Phase 1 / Dose Escalation)
Secondary: Area under the curve (AUC) of STP938 including effects of food on absorption (Phase 1 / Dose Escalation), Evaluate best overall response of STP938 (Phase 1 / Phase 2), Evaluation Duration of Response (Phase 1 / Phase 2), Evaluation Progression Free Survival (Phase 1 / Phase 2), Evaluation of Complete Response Rate (Phase 2), Maximum plasma concentration (Cmax) of STP938 including effects of food on absorption (Phase 1 / Dose Escalation), Safety and Tolerability (Phase 2 / Dose Expansion), Time to reach maximum concentration (TMax) of STP938 including effects of food on absorption (Phase 1 / Dose Escalation)
Oncology